Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine; Gouji Toyokawa; Tetsuzo Tagawa; Takashi Seto

doi:10.21037/jtd.2018.07.92

Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, Takashi Seto

呼吸器外科(2)

研究成果: ジャーナルへの寄稿 › 総説 › 査読

5 被引用数 (Scopus)

本文言語	英語
ページ（範囲）	S3155-S3159
ジャーナル	Journal of Thoracic Disease
巻	10
DOI	https://doi.org/10.21037/jtd.2018.07.92
出版ステータス	出版済み - 9月 1 2018

!!!All Science Journal Classification (ASJC) codes

呼吸器内科

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.21037/jtd.2018.07.92

他のファイルとリンク

引用スタイル

@article{d9d91f2be8374f158ef44961bfff2434,

title = "Atezolizumab in non-squamous non-small cell lung cancer",

author = "Takaki Akamine and Gouji Toyokawa and Tetsuzo Tagawa and Takashi Seto",

note = "Funding Information: Yakuhin, Eisai, Merck Serono, Novartis Pharma, and Verastem; personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, Roche Singapore, Sanofi, Showa Yakuhin, Taiho Pharmaceutical and Takeda Pharmaceutical; grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Pfizer Japan, YakultHonsha, outside the submitted work. The other authors have no conflicts of interest to declare.",

year = "2018",

month = sep,

day = "1",

doi = "10.21037/jtd.2018.07.92",

language = "English",

volume = "10",

pages = "S3155--S3159",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - Atezolizumab in non-squamous non-small cell lung cancer

AU - Akamine, Takaki

AU - Toyokawa, Gouji

AU - Tagawa, Tetsuzo

AU - Seto, Takashi

N1 - Funding Information: Yakuhin, Eisai, Merck Serono, Novartis Pharma, and Verastem; personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, Roche Singapore, Sanofi, Showa Yakuhin, Taiho Pharmaceutical and Takeda Pharmaceutical; grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Pfizer Japan, YakultHonsha, outside the submitted work. The other authors have no conflicts of interest to declare.

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85053763722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053763722&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.07.92

DO - 10.21037/jtd.2018.07.92

M3 - Review article

AN - SCOPUS:85053763722

SN - 2072-1439

VL - 10

SP - S3155-S3159

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

ER -